Caribou Biosciences, Inc.
NMS: CRBULive Quote
📈 ZcoreAI Score
Our AI model analyzes Caribou Biosciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CRBU Z-Score →About Caribou Biosciences, Inc.
Healthcare
Biotechnology
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
📊 Fundamental Analysis
Caribou Biosciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 89.7% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -79.0%, which indicates that capital utilization is currently under pressure.
At a current price of $1.93, CRBU currently sits at the 43rd percentile of its 52-week range (Range: $0.71 - $3.54).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$186.51M
Trailing P/E
--
Forward P/E
-1.29
Beta (5Y)
2.46
52W High
$3.54
52W Low
$0.71
Avg Volume
1.23M
Day High
Day Low